Boehringer Ingelheim said Friday that it will halt development of BI 409306 in Alzheimer's disease after Phase II studies of the PDE9A inhibitor failed to meet their efficacy endpoints. The company indicated that it will instead refocus efforts for the drug on ongoing schizophrenia trials."This is what research is about: disappointments are a daily experience in science, but even these clinical trial results will add to the understanding of brain function and contribute to future progress in this area," remarked Jan Poth, therapeutic area head of CNS diseases at Boehringer Ingelheim.BI 409306 was investigated in two studies designed to show superiority of the drug over placebo in cognition, with top-line data pooled for analysis. The trials included 457 patients with cognitive impairment due to Alzheimer's disease. Boehringer Ingelheim said that following a comprehensive r
………………………………
